Tag: infection

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ^® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ^®. IXCHIQ^® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.

Endocarditis, a heart infection caused by bacteria in the bloodstream, is experiencing growing incidence due to rising healthcare-associated infections, intravenous drug use, and aging populations with prosthetic valves. Advances in diagnostic imaging, AI-assisted echocardiography, and minimally invasive cardiac procedures are improving detection and patient outcomes. However, challenges like early detection difficulties and antimicrobial resistance persist. North America leads in the endocarditis market, with significant growth seen in the Asia-Pacific due to increased cardiovascular cases and healthcare investments. Key players like Pfizer and Teva Pharmaceutical are driving innovations in the sector.